Drug Database
LO

losartan + HCTZ (Gizaar / Hyzaar / Cozaar plus)

✓ Approved

Merck & Co. · AGTR1 · Small Molecule

What is losartan + HCTZ?

losartan + HCTZ is a small molecule developed by Merck & Co.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesGizaar, Hyzaar, Cozaar plus
CompanyMerck & Co.
Drug ClassSmall Molecule
Molecular TargetAGTR1, SLC12A3
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

losartan + HCTZ acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

losartan + HCTZ is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedJournal of oral rehabilitation2026-07-25

Is Capsaicin Effective in Relieving the Symptoms of Burning Mouth Syndrome? A Systematic Review.

de Andrade Silva Ana Paula AP, Dos Santos Ian Wesley Rocha IWR, da Silva Zuleni Alexandre ZA, Frazão Deborah Ribeiro DR et al.

Burning Mouth Syndrome (BMS) is a type of chronic orofacial pain characterised by a burning sensation inside the mouth without an apparent cause. Capsaicin has been used to manage the symptoms of this syndrome, but there is still no consensus on its effectiveness. To assess whether capsaicin, when used topically or systemically, is able to alleviate the symptoms of BMS. An extensive search was carried out in seven databases and grey literature up to November 2025. There were no restrictions regarding the date or language of publication. The search resulted in 782 articles, of which 4 were included. The methodological quality of the studies was assessed using the Risk of Bias in Systematic Reviews (ROBIS) tool and the certainty of evidence was performed according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE). Regarding capsaicin administration, 3 studies used topical application and 1 used systemic application. Concentrations ranged from 0.000354% to 0.25%, three times a day, for 1-8 weeks. Regardless of the administration method, a reduction in patient-reported pain scores was observed. Risk of bias assessment showed that three randomised studies presented a moderate risk, while the only non-randomised clinical trial presented a critical risk. The overall certainty of the evidence was low or very low for the outcomes assessed. Evidence suggests that capsaicin is effective in relieving BMS symptoms. However, this result should be interpreted with caution due to the low quality of the evidence obtained to support its use.

PubMedPrecision radiation oncology2026-07-25

Nomogram integrating MRI radiomics and white matter hyperintensity grading for predicting overall survival in patients with non-small cell lung cancer and brain metastases receiving whole-brain radiotherapy.

Ni Jianan J, Lu Yuefeng Y, Xu Haoli H, Xu Xuni X et al.

To develop and validate a nomogram integrating radiomic features, white matter hyperintensity (WMH) grading, and clinical factors for predicting overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs) receiving whole-brain radiotherapy (WBRT). One hundred and forty-nine patients with BMs were enrolled. A radiomic score (Rad-score) was developed based on features identified by univariate Cox regression and least absolute shrinkage and selection operator Cox modeling. WMH was graded using the Fazekas scale, into mild- and extensive-burden groups. Cox proportional hazard models incorporating different combinations of these features were developed and compared. A nomogram was constructed by integrating the Rad-score, WMH grade, and independent clinical variables, and its performance was evaluated using receiver operating characteristic (ROC) analysis, decision curve analysis (DCA), and calibration plots. Twelve radiomic features were identified. Both the Rad-score (hazard ratio (HR) = 1.072; P < 0.001) and WMH grade (HR = 2.420; P < 0.001) independently and significantly predicted OS. Significant improvements in model fit followed the inclusion of these variables (P < 0.01). The integrated nomogram outperformed the single-feature models, yielding area under the curves (AUCs) of 0.820, 0.900, and 0.889 for 1-, 2-, and 3-year OS, respectively, with a concordance index (C-index) of 0.706 (95% CI: 0.598-0.815). Calibration plots and DCA further supported the predictive accuracy and clinical utility. The radiomics- and WMH grading-based nomogram represents a potential prognostic tool for patients with NSCLC and BMs receiving WBRT.

PubMedOncogene2026-07-25

RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer via the methylation-dependent and independent dual functions of DNMT1.

Wang Ke-Jie KJ, Wang Kai-Yun KY, Chen Si-Xi SX, Ma Yu-Tao YT et al.

Acquired resistance to the CYP17 inhibitor abiraterone is a critical challenge in the clinical treatment of metastatic prostate cancer; however, the mechanisms driving this resistance remain elusive. This study suggests that aberrant RON expression plays an important role in the development of acquired abiraterone resistance in prostate cancer cells. Increased RON expression was observed in most clinical tumor samples with an abiraterone-insensitive phenotype. In established prostate cancer cell lines, aberrant RON expression is associated with increased abiraterone resistance and enhanced migratory activity. These effects are mediated through dual regulatory functions of DNA methyltransferase 1(DNMT1): RON-mediated regulation of the canonical methyltransferase activity of DNMT1, which inhibits receptor-interacting protein kinase 3(RIPK3) expression, leading to increased cellular survival with impaired RIPK3/MLKL-involved cell death signaling. Concurrently, RON-driven non-methyltransferase activity of DNMT1 is associated with altered mitochondrial functions, thereby potentially enhancing cellular migration. The multi-kinase inhibitor BMS-777607, which has activity against RON, in combination with abiraterone suppressed both proliferation and metastasis in abiraterone-resistant xenograft tumors. The discovery of the RON-DNMT1-RIPK3 functional axis and the association between RON-DNMT1 and mitochondrial bioenergetic activity in this work strongly suggest RON as a critical driver of abiraterone resistance and a potential therapeutic target in prostate cancer.

PubMedThe American journal of case reports2026-07-25

A 46-Year-Old Man Presenting With Chest Pain Due to Apical Hypertrophic Cardiomyopathy (Yamaguchi Syndrome) Diagnosed by Multimodal Cardiac Imaging.

Passos Mauro de Deus MD, de Araújo Daniel Lopes Marques DLM, Mariano Lucas de Ávila LÁ, Ferreira Dilson Palhares DP et al.

BACKGROUND Apical hypertrophic cardiomyopathy (ApHCM), also known as Yamaguchi syndrome, is a rare variant of hypertrophic cardiomyopathy characterized by the thickening of the left ventricle apex (>15 mm) and giant negative T-waves on the precordial leads of the electrocardiogram (ECG), which can present symptoms and electrocardiographic changes that mimic acute coronary syndrome (ACS). This report describes the case of a 46-year-old man with chest pain and giant T-wave inversion on ECG, requiring multimodal cardiac imaging to diagnose ApHCM (Yamaguchi syndrome) and exclude the diagnosis of coronary artery occlusion and myocardial infarction. CASE REPORT We report the case of a 46-year-old man who presented to the Emergency Department with typical chest pain. His ECG revealed significant alterations highly suggestive of ACS, including ST-segment depression and giant negative T-waves (>10 mm) in leads V4-V6. Despite this presentation, serial high-sensitivity troponin levels remained consistently within the normal range. Coronary computed tomography angiography (CCTA) revealed non-obstructive coronary arteries but indicated increased apical left ventricular (LV) wall thickness with characteristic trabeculation, raising suspicion for ApHCM. Transthoracic echocardiography (TTE) confirmed pronounced apical LV thickening (20 mm) and a reduced Global Longitudinal Strain (GLS) of -14.3%. Cardiac magnetic resonance (CMR) imaging provided a definitive diagnosis, identifying significant apical hypertrophy with systolic obliteration of the LV cavity and quantifying multifocal myocardial fibrosis at 6% of the LV mass. The patient's symptoms improved significantly with medical therapy, including losartan, metoprolol, and trimetazidine. CONCLUSIONS This case highlights the critical diagnostic challenge of ApHCM masquerading as ACS. It underscores the indispensable role of a multimodal imaging approach-integrating ECG, TTE, CCTA, and CMR-for an accurate diagnosis, particularly for identifying underlying myocardial fibrosis and guiding appropriate patient management.

PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-07-25

Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy.

Zou Wei W, Li Tianle T, Plewka Jacek J, Song Xiaoxiong X et al.

Given the limitations of the existing monoclonal antibody (mAb)-based therapies, more efficient and safer small-molecule-based checkpoint therapies targeting the programmed cell death-1 (PD-1) / programmed cell death ligand-1 (PD-L1) axis are gaining growing attention and urgently required. To identify a novel PD-L1 small-molecule inhibitor from natural products and systematically evaluate its antitumor activity, mechanism of action, and potential biomarkers. Based on the co-crystal structure of PD-L1 with BMS-202 (PDB ID: 5J89), molecular docking was employed for high-throughput virtual screening of 16,563 natural products. The binding affinity of candidate compounds to PD-L1 protein was validated through microscale thermophoresis (MST), cellular thermal shift assay (CETSA), drug affinity responsive target stability (DARTS) assays and nuclear magnetic resonance (NMR). The blockade of PD-1/PD-L1 interaction was assessed using homogeneous time-resolved fluorescence (HTRF), NFAT-Luc luciferase reporter gene system, and cell membrane PD-1 binding assays. In vivo antitumor efficacy was systematically assessed in humanized PD-L1 knock-in B16F10 and MC38 tumor-bearing mouse models. The mechanism of action was investigated using RNA-seq transcriptomics, flow cytometry, and immunofluorescence staining. Finally, response mechanisms and potential biomarkers were systematically analyzed by comparing differential responses across distinct tumor models. Through high-throughput virtual screening, we identified rosavin as a small molecule with a novel scaffold that targets PD-L1, exhibiting the unusual small-molecule property of inhibiting PD-L1 without inducing its dimerization. Rosavin demonstrated significant antitumor activity in vivo by promoting antitumor immunity through enhancing CD8+ T cell activation, consistent with the effects of PD-L1/PD-1 blockade. Notably, rosavin was particularly effective for fighting against tumor progression in microsatellite instability-high (MSI-H) solid tumors and robustly strengthened the expression levels of CXCL9 and CXCL10 in tumors, which may serve as potential biomarkers for predicting responsiveness to rosavin-mediated PD-1/PD-L1 blockade. Rosavin serves as a privileged novel and unexpected scaffold for designing potent PD-1/PD-L1 modulators, offering promising candidates for cancer immunotherapy.

PubMedInternational journal of burns and trauma2026-07-23

A novel forward-deployed damage control orthopedics: Battlefield Monitoring and Stabilization (BMS).

Liu Shu S, Sui Junhao J, Lou Wei W, Xue Qian Q et al.

Delayed evacuation creates a critical gap between point-of-injury care and definitive surgical management in battlefield trauma. Although Damage Control Orthopedics (DCO) is an established strategy for physiologically unstable trauma patients, it is usually implemented after evacuation and depends on higher-level medical support. We propose Battlefield Monitoring and Stabilization (BMS) as a forward-deployed conceptual framework for earlier battlefield care. BMS emphasizes temporary stabilization, hemorrhage-oriented intervention, basic physiological support, and portable monitoring before evacuation and definitive treatment. Proposed applications include point-of-injury stabilization, prolonged field care, and en-route casualty management. Several enabling components, including a rapidly assembled pelvic stabilization device, are under development. Relevant evaluation domains include fixation speed, hemostatic performance, monitoring accuracy, portability, and environmental adaptability. Further validation is warranted.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about losartan + HCTZ